Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: To test whether a long‐acting GLP‐1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we sought to determine whether the drug would affect beta cell function. Methods: We performed a randomized placebo‐controlled trial of exenatide extended release (ER) in participants with T1D with and without detectable levels of C‐peptide. Seventy‐nine participants were randomized to exenatide ER 2 mcg weekly, or placebo, stratified by the presence or absence of detectable C‐peptide levels. The primary outcome was the difference in glycated haemoglobin (HbA1c) levels at 24 weeks. Participants were followed for another 6 months off study drug. Results: At week 24, the time of the primary outcome, the least squares (LS) mean HbA1c level was 7.76% (95% confidence interval [CI] 7.42, 8.10) in the exenatide ER group versus 8.0% (95% CI 7.64, 8.35) in the placebo group ( P = 0.08). At week 12 the LS mean HbA1c levels were 7.71% (95% CI 7.37, 8.05) in the exenatide ER group versus 8.05% (95% CI 7.7, 8.4) in the placebo group ( P = 0.01). The improvement at week 12 was driven mainly by those with detectable levels of C‐peptide. Those treated with exenatide ER lost weight at 12 and 24 weeks compared to those treated with placebo ( P <0.001 and P = 0.007). The total insulin dose was lower, but not when corrected for body weight, and was not affected by residual insulin production. Adverse events were more frequent with exenatide ER, but hypoglycaemia was not increased. Conclusion: Treatment with exenatide ER may have short‐term benefits in some individuals with T1D who are overweight or who have detectable levels of C‐peptide, but short‐term improvements were not sustained.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“Because GLP-1RAs are known to augment insulin production we predicted a greater treatment effect in those with residual insulin secretion but, similar to our acute studies, the metabolic effects of the drug were not limited to those with residual insulin secretion.(2,15) Our findings were similar even when we separate…”
ResultBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070 · cited 2×
“First, exenatide ER had been shown to reduce glucagon levels in patients with T2D, but we did not observe this during the provocative studies.(3) This may reflect a relative insensitivity or dysregulation of α cells in patients with T1D to the effects of the agonist, which had been observed in acute studies.”
ResultRawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802
Statistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652 · cited 1×
“A likelihood-based ignorable analysis using a linear mixed model was used to compare HbA1c between groups.(18,19) The analysis assumed that missing data”
MethodEstimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010
Livingstone, S. J., Levin, D., Looker, H. C., Lindsay, R. S., Wild, S. H., Joss, N., Leese, G., Leslie, P., McCrimmon, R. J., Metcalfe, W., et al. (2015) · JAMA · doi:10.1001/jama.2014.16425 · Cited by 621
Keenan, H. A., Sun, J. K., Levine, J., Doria, A., Aiello, L. P., Eisenbarth, G., Bonner-Weir, S., & King, G. L. (2010) · Diabetes · doi:10.2337/db10-0676 · Cited by 500
Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators (2016) · Diabetes Care · doi:10.2337/dc16-0691 · Cited by 347
Oram, R. A., Jones, A. G., Besser, R. E. J., Knight, B. A., Shields, B. M., Brown, R. J., Hattersley, A. T., & McDonald, T. J. (2014) · Diabetologia · doi:10.1007/s00125-013-3067-x · Cited by 298 · cited 1×
“Many patients, even those with long-standing T1D, may have detectable levels of C-peptide well beyond the newonset period.(6,7) Tropic effects of exendin-4 on β cells were shown in rodents after partial pancreatectomy, and synergy with immune therapy at the time of diabetes onset enhanced the insulin content of β cell…”
BackgroundAhrén, B., Hirsch, I. B., Pieber, T. R., Mathieu, C., Gómez-Peralta, F., Hansen, T. K., Philotheou, A., Birch, S., Christiansen, E., Jensen, T. J., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0690 · Cited by 262 · cited 2×
“weight and insulin requirements, but with higher rates of hypoglycaemia and ketosis.(13) The differences between the adverse events in the present study and the ADJUNCT trials may reflect our”
BackgroundSherry, N. A., Chen, W., Kushner, J. A., Glandt, M., Tang, Q., Tsai, S., Santamaria, P., Bluestone, J. A., Brillantes, A.-M. B., & Herold, K. C. (2007) · Endocrinology · doi:10.1210/en.2007-0358 · Cited by 169 · cited 1×
“Tropic effects of exendin-4 on β cells were shown in rodents after partial pancreatectomy, and synergy with immune therapy at the time of diabetes onset enhanced the insulin content of β cells.(8,9) Data from human studies have identified impaired function of residual β cells in patients with T1D, thus further support…”
BackgroundSelf-citationRother, K. I., Spain, L. M., Wesley, R. A., Digon, B. J., Baron, A., Chen, K., Nelson, P., Dosch, H.-M., Palmer, J. P., Brooks-Worrell, B., et al. (2009) · Diabetes Care · doi:10.2337/dc09-0773 · Cited by 133
Exenatide treatment for 6 months improves insulin sensitivity in adults with type 1 diabetes
Sarkar, G., Alattar, M., Brown, R. J., Quon, M. J., Harlan, D. M., & Rother, K. I. (2014) · Diabetes Care · doi:10.2337/dc13-1473 · Cited by 74
Cited by
Glucagon-Like Peptide 1 Receptor Agonists and Mental Health: A Systematic Review and Meta-Analysis
Pierret, A. C. S., Mizuno, Y., Saunders, P., Lim, E., De Giorgi, R., Howes, O. D., McCutcheon, R. A., McGowan, B., Sen Gupta, P., Smith, D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.0679 · Cited by 116
Park, J., Ntelis, S., Yunasan, E., Downton, K. D., Yip, T. C.-F., Munir, K. M., & Haq, N. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad471 · Cited by 69
Arredouani, A. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108824 · Cited by 36
Yu, J., Shi, Y.-C., Ping, F., Li, W., Zhang, H.-B., He, S.-L., Zhao, Y., Xu, L.-L., & Li, Y.-X. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.763646 · Cited by 27
Kolli, R. T., Aoutla, S., Jyothi, N., Mohamed Kalifa, M. R. H., Raju, A., & Cheenikkal Muralidharan, K. (2025) · Cureus · doi:10.7759/cureus.94926 · Cited by 7
Metadata
- Authors
- Herold, K. C., Reynolds, J., Dziura, J., Baidal, D., Gaglia, J., Gitelman, S. E., Gottlieb, P. A., Marks, J., Philipson, L. H., Pop‐Busui, R., & Weinstock, R. S.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2020-07-29
- Volume
- 22
- Issue
- 11
- Pages
- 2045-2054
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W3036339650
- Cited by
- 41
- References
- 13
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.